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Conclusion: Strong correlations between predicted and 
achieved mean OAR doses indicates that RapidPlan could 
accurately predict achievable mean doses, showing the 
feasibility of using RapidPlan DVH predictions alone for 
automated individualized HNC plan QA. Since this QA 
approach does not require the creation of additional plans, 
these findings indicate that automated individualized plan QA 
is now a realistic proposition for individual centers and 
clinical trials. 
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Purpose or Objective: Image guided robotic stereotactic 
radiotherapy (SRT) is becoming increasingly commonly used 
in the treatment of prostate cancer. As SRT treatment may 
consist of 100-300 small beams, the dose-rate (DR) and thus 
the biologically effective dose (BED) can vary significantly 
within the target volume, despite the creation of a very 
uniform total physical dose distribution (1). However, the 
significance of the spatial variations in DR on BED in robotic 
SRT treatments remains unknown.  
The aim of the present study is to measure the DR 
distribution, with treatment progression, in a representative 
robotic SRT treatment for prostate cancer and to investigate 
the effect of these spatial and time related variations in the 
measured DR on the calculated BED. 
 
Material and Methods: A representative robotic SRT 
treatment plan for prostate cancer (5 x 7.25 Gy, 222 beams, 
treatment time 28 min) was created with the Multiplan 
treatment planning software (v 4.6.0., Accuray, USA). Based 
on this plan a quality assurance plan was calculated for a 
MultiCube phantom incorporating a MatriXX Detector (32 x 32 
matrix of ionization chambers) spatial resolution 7.6 mm, 
time resolution 0.5 s (IBA Dosimetry, Germany). The DR 
distributions were measured in four different coronal planes 
(separated by 1cm) covering the volume of the target 
structure to create a 3D DR distribution. Then BED values, 
calculated using bi-exponential repair (repair half times 0.2 h 
and 2.5 h, α/β =1.5Gy) were calculated for each voxel based 
on the measured DR (BED_M), average dose-rate (measured 
dose divided by the overall treatment time, BED_A) and 
physical dose (measured dose without the repair component, 
BED_P) distributions.  
 
Results: Compared to the BED_P, where no repair was 
allowed for, both BED_M and BED_A values, within the target 
volume, were significantly lower (Fig 1). Furthermore, BED_M 
values were found to be systematically higher than BED_A 
values. Significant variation was observed in BED_M values 
corresponding to the same BED_P value (Fig 1). This effect 
was not observed with BED_A values (Fig 1). 
 
 
 
Figure 1. A: Representative SRT plan, B: corresponding BED_P 
values, C: Frequency distributions of BED_P, BED_M and 
BED_A values within the target volume, D: Range of BED_M or 
BED_A values corresponding uniform BED_P value.  
 
Conclusion: The simple us of the average DR in the 
determination of BED does not take into account the 
variations in the spatial DR, and this leads to an 
underestimation of BED values. Furthermore, significant 
variations were observed in BED_M values when compared to 
uniform BED_P values, an observation also consistent with 
comparable Gamma Knife treatments (1). Thus, the actual 
and not the average DR should be used in the calculation of 
BED when the efficacy of the SRT treatments is evaluated or 
different treatment modalities are compared. 
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Learning Objectives 
 
At the end of this talkyou will have a better awareness of: 
1. reasons why educational ‘science’ may be overlooked 
2. how principles of adult learning might apply to radiation 
oncology 
3. potential benefits of applying an evidence-based approach 
to educationalactivities  
Radiation Oncology is adiscipline with a history firmly 
founded on the sciences of radiobiology,radiation physics, 
anatomy, pathology and clinical medicine that remain 
asrelevant as ever to its exciting future. An evidence-based 
approach to practiceand progress in our field is seen as core 
to our identity as radiation oncologyprofessionals. 
So how can it be thatthe ‘science’ of teaching the next 
generation of practitioners, as well as thecurrent one 
(ourselves), especially in such a rapidly changing arena, is 
oftenleft to chance? Why is so little focus placedon the 
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health education literature and scholarship in this area? And 
why do weaccept that random and variable acquisition of 
knowledge and skills, irrespectiveof the evidence for 
pedagogical best-practice, is good enough for our 
specialtyand for our patients? 
This talk will dealwith possible reasons that we may be 
blinkered to important aspects of learningin radiation 
oncology. It will outline the knowledge that we do have to 
guide us, and the benefits ofworking more cooperatively in 
education across professions and jurisdictions.By paying 
attention to the ‘forgotten foundation’, that of high quality 
teachingand training, we dramatically enhance our chances 
of achieving the goals in quality,safety, effectiveness and 
leadership in cancer patient management, for which 
westrive. 
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The role of cancer surgery has been consolidated over the 
years but drastic changes are taking place and Surgical 
Oncologists need to be prepared for substantial changes. 
Traditionally, cancer treatment rested on tissue diagnosis: a 
sample of the affected area is taken, analyzed and classified 
according to its morphology. “Tissue diagnosis” results into 
“tissue-based treatment”. As times are rapidly changing and 
we are becoming accustomed to “molecular diagnosis”, 
leading to “genetically informed treatment plans”, surgical 
oncologists should be up to date with newly described 
diagnostic and therapeutic options. Genetic counseling is also 
reshaping: lo prevalence (but high penetrance) genes have 
been associated to the risk of developing breast cancer; more 
interestingly, several other genetic markers (high prevalence 
but low penetrance) are being identified. Improved 
understanding of their specific role will twist the way family 
clinics are run. Advanced diagnostic tools are being 
developed and their availability will also modify the way we 
treat patients: digital tomosynthesis will probably 
reconfigure breast cancer screening; liquid biopsy is slowly 
but steadily being introduced into clinical practice, in view of 
optimizing neoadjuvant treatment as well as palliative 
treatment, the whole practice of follow-up and other steps of 
clinical practice. A multidisciplinary approach is mandatory – 
it is a condition sine qua non for the surgical oncologist to 
understand issues and problems from the point of view of 
medical and radiation oncologists radiologists and 
pathologists, without dismissing nurses and social workers, 
psycho-oncologists, geneticists, an others. Complex and 
inter-specialty treatment options are becoming routine (e.g. 
intra-operative radiotherapy). The success of new treatment 
plans will necessarily open new, previously unthinkable, 
therapeutic options. Patients’ advocacy and a sympathetic 
approach is extremely rewarding, beside science and 
research. Patients are at the center of our practice and social 
mandate. It is therefore to keep in mind the complexity of 
issues affecting cancer patients, cancer survivors and their 
relatives in their every day’s life. Education is significantly 
modified, with remote-learning and training labs becoming 
available; virtual education is becoming popular and 
relatively in-expensive and young generations are rather 
accustomed to such new educational tools. The ongoing 
attempt in homogenizing education with other international 
tween societies aims to allowing exchanges, improving 
knowledge and boosting cross-fertilization. The political role 
of cancer surgeons should be kept in mind at all times, with 
surgeons firmly determined to play a substantial part within 
the multidisciplinary oncology team. 
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Lung cancer is still today the leading cause of death 
worldwide despite the availability of a variety of treatments. 
In particular Radiation Oncology is widely involved in lung 
cancer management, both as a neo or adjuvant therapy as 
well as a definitive one.  
As the suffix “Radio-“ suggests, the Radiologist and the 
Radiotherapist have been “step-brothers” since their origins, 
as co-actors in the main steps of treatment: staging / 
treatment planning and follow-up.  
An accurate staging is essential in treatment planning in 
order to include macro- and micro-scopic cancer and to avoid 
unwanted toxicities. Lung injury is common in patients 
treated with Radiotherapy. The knowledge of radiological 
patterns of lung abnormalities after non surgical treatments 
is critical to accurately assess the overall effectiveness of 
these therapies and to differentiate normal appearances 
from incomplete treatments and/or local recurrences. 
Nowadays, a new multidisciplinary challenge for our 
disciplines is required: the “individualized medicine”. The 
idea is to “design” a patient personalized therapy by 
identifying and integrating multimodal prognostic factors in 
models of treatment outcomes and also in clinical-decision 
support systems. Clinical imaging is particularly involved in 
this new field, the so-called “Radiomics” process, which 
offers a comprehensive and non-invasive “photograph” of 
patients and cancer heterogeneity. 
Indeed in recent years we have witnessed a continual 
evolution of both Radiology and the Radiologist. Diagnostic 
Imaging has moved from focusing on image quality to a 
molecular level, from pictures to data. An important 
contribution has been provided by nuclear medicine, not only 
in identifying pathological sites, but also in outlining more 
active components. The “anatomical” evolution has offered 
the Radiotherapist the capability to better define the target 
and the “functional” evolution the capability to select the 
right one. The Radiologist, similarly, has evolved from a 
photographer to an interpreter and, in the future, will 
become a decision maker.  
The aim of this lecture is to make a “journey” through the 
evolving role of the doctor as an “image artist” of lung 
cancer Radiotherapy.  
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Dysregulation of the DNA damage response (DDR) is 
associated with a predisposition to cancer and affects 
responses to DNA-damaging anticancer therapies. 
Dysregulation of a certain DNA repair pathway may be 
